Taysha Gene Therapies, Inc. (TSHA)

Taysha Gene Therapies, Inc. (TSHA) is a healthcare company (biotechnology) based in the United States. The share price is $4.02, down 1.11% on the day, which values the company at $1.31B. Price as of 17 Nov 2026, 17:28 UTC, from Yahoo Finance.

Key facts

Share price
$4.02−1.11% today
Market value
$1.31B
Funk Score
45/100
Against its own history
Well above its usual priceusual price $3.04
200-week average
$2.9337% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Taysha Gene Therapies, Inc. in more detail

TSHA trades at -10.4× next year's expected earnings, 238.7× sales. Measured against its own history, the price is 32% above what its usual multiples would imply ($3.04) — well above its usual price. It sits 37% above its 200-week average of $2.93.

Its Funk Score is 45 out of 100 (financial strength 6.3, profitability 2.5, growth 8.3, value 1.0, each out of 10).

In its favour: Altman Z in the safe zone; More cash than debt. Worth checking: Share count keeps rising; Thin interest cover.

4 of the superinvestors tracked here hold TSHA, including Peter Kolchinsky (1.4% of the portfolio), Julian and Felix Baker (0.1% of the portfolio), Andrew Spokes (0.1% of the portfolio).

Superinvestors holding TSHA

4 of the investors tracked here report a position in their latest 13F filing.

Taysha Gene Therapies, Inc. (TSHA): questions and answers

What is Taysha Gene Therapies, Inc.'s market cap?

Taysha Gene Therapies, Inc. is valued at $1.31B at a share price of $4.02.

Is TSHA overvalued or undervalued?

Against its own history, TSHA is well above its usual price: the price is 32% above the $3.04 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is TSHA above its 200-week moving average?

Yes. TSHA is 36.9% above its 200-week average of $2.93. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Taysha Gene Therapies, Inc. growing?

Over the last three fiscal years Taysha Gene Therapies, Inc.'s revenue grew 57.5% a year.

Does TSHA pay a dividend?

Taysha Gene Therapies, Inc. does not currently pay a regular dividend.

Which famous investors own TSHA?

In their latest quarterly filings, Peter Kolchinsky (1.4% of the portfolio), Julian and Felix Baker (0.1% of the portfolio), Andrew Spokes (0.1% of the portfolio), Polen Capital team (0.0% of the portfolio) hold TSHA. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Taysha Gene Therapies, Inc. (TSHA) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/TSHA

Underlying data: Yahoo Finance; company filings with the SEC.